- Conditions
- Hepatitis C Virus
- Interventions
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Bakersfield, California • Jacksonville, Florida • Lutherville, Maryland + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 7,623
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastrointestinal Neoplasms
- Interventions
- IDRX-42, Sunitinib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 42 more
- Conditions
- Bleeding Active
- Interventions
- CELSTAT, Surgicel Original
- Device
- Lead sponsor
- Baxter Healthcare Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 19
- States / cities
- Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 14 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ublituximab, Umbralisib, Venetoclax
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- bevacizumab, placebo, erlotinib HCl
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 177
- States / cities
- Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more
- Conditions
- Arrhythmias, Cardiac, Heart Diseases, Cardiovascular Diseases, Implantable Cardioverter Defibrillator
- Interventions
- Azimilide Dihydrochloride, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 72 more
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Amnion-Intermediate-Chorion, Standard of Care (SOC)
- Other · Procedure
- Lead sponsor
- Cellution Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 8
- States / cities
- Santa Rosa, California • Jacksonville, Florida • Chicago, Illinois + 5 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 35
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Oceanside, California + 31 more
- Conditions
- Breast Carcinoma
- Interventions
- Biospecimen Collection, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Heart Failure
- Interventions
- BNP
- Diagnostic Test
- Lead sponsor
- Beckman Coulter, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 17
- States / cities
- Loma Linda, California • Sacramento, California • Gainesville, Florida + 14 more
- Conditions
- Refractory Multiple Myeloma
- Interventions
- pomalidomide, bortezomib, dexamethasone, laboratory biomarker analysis, gene expression analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2, Placebo, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI, Combination (Bivalent) BNT162b2 and BNT162b2 OMI
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 16,372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 139
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 99 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis
- Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14,532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 93
- States / cities
- Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 82 more
- Conditions
- Pareses, Lower Extremity
- Interventions
- C-Brace
- Device
- Lead sponsor
- Otto Bock Healthcare Products GmbH
- Industry
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 70
- States / cities
- Harrison, Arkansas • Rogers, Arkansas • San Diego, California + 63 more
- Conditions
- Breast Cancer
- Interventions
- erlotinib hydrochloride, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 22 more
- Conditions
- Low Back Pain
- Interventions
- celecoxib, tramadol HCL
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
- Conditions
- Endotracheal Intubation
- Interventions
- Endotracheal Intubation at TOFC=1, Endotracheal Intubation 2 minutes after rocuronium administration
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
- Interventions
- Vamifeport, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • San Diego, California • Jacksonville, Florida + 16 more
- Conditions
- Pancreatic Cancer
- Interventions
- Pegilodecakin, FOLFOX
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 57
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 49 more
- Conditions
- Stage III Vulvar Cancer, Stage IVB Vulvar Cancer, Vulvar Squamous Cell Carcinoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Cisplatin, Conventional Surgery
- Radiation · Drug · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 81 more
- Conditions
- PNH
- Interventions
- Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more
- Conditions
- Sudden Cardiac Death
- Interventions
- Arm 1 (ATP+Shock), Arm 2 (shock only)
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 2,692 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 89
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Interventions
- Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention, Not Randomized to Device or Medication Intervention
- Device · Other
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 826 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 53
- States / cities
- Mesa, Arizona • Jonesboro, Arkansas • Mission Viejo, California + 47 more
- Conditions
- Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 1,673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 928
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more